NO326856B1 - Farmasoytisk sammensetning samt anvendelse av et progestin - Google Patents
Farmasoytisk sammensetning samt anvendelse av et progestin Download PDFInfo
- Publication number
- NO326856B1 NO326856B1 NO20002084A NO20002084A NO326856B1 NO 326856 B1 NO326856 B1 NO 326856B1 NO 20002084 A NO20002084 A NO 20002084A NO 20002084 A NO20002084 A NO 20002084A NO 326856 B1 NO326856 B1 NO 326856B1
- Authority
- NO
- Norway
- Prior art keywords
- progestin
- progesterone
- bleeding
- composition
- administration
- Prior art date
Links
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title claims description 183
- 239000000583 progesterone congener Substances 0.000 title claims description 71
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 12
- 230000000740 bleeding effect Effects 0.000 claims description 57
- 229960003387 progesterone Drugs 0.000 claims description 56
- 239000000186 progesterone Substances 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 32
- 229920000642 polymer Polymers 0.000 claims description 31
- 201000000736 Amenorrhea Diseases 0.000 claims description 17
- 206010001928 Amenorrhoea Diseases 0.000 claims description 17
- 231100000540 amenorrhea Toxicity 0.000 claims description 17
- 239000000227 bioadhesive Substances 0.000 claims description 15
- 125000004122 cyclic group Chemical group 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000001737 promoting effect Effects 0.000 claims description 5
- 206010051909 Endometrial atrophy Diseases 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 description 55
- 208000034158 bleeding Diseases 0.000 description 55
- 239000000499 gel Substances 0.000 description 21
- 230000002354 daily effect Effects 0.000 description 20
- 238000009472 formulation Methods 0.000 description 19
- 238000002657 hormone replacement therapy Methods 0.000 description 15
- 229940000593 crinone Drugs 0.000 description 14
- 239000000262 estrogen Substances 0.000 description 13
- 229940011871 estrogen Drugs 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 210000004696 endometrium Anatomy 0.000 description 8
- 230000009245 menopause Effects 0.000 description 7
- 150000003431 steroids Chemical class 0.000 description 7
- 238000002604 ultrasonography Methods 0.000 description 7
- 230000002357 endometrial effect Effects 0.000 description 6
- 229920002125 Sokalan® Polymers 0.000 description 5
- 230000035587 bioadhesion Effects 0.000 description 5
- -1 glucocorticoids Chemical class 0.000 description 5
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 5
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 229920000148 Polycarbophil calcium Polymers 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 238000009164 estrogen replacement therapy Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- KUQWZSZYIQGTHT-UHFFFAOYSA-N hexa-1,5-diene-3,4-diol Chemical compound C=CC(O)C(O)C=C KUQWZSZYIQGTHT-UHFFFAOYSA-N 0.000 description 4
- 230000001788 irregular Effects 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 229950005134 polycarbophil Drugs 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 235000019482 Palm oil Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 239000002540 palm oil Substances 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 235000010199 sorbic acid Nutrition 0.000 description 3
- 239000004334 sorbic acid Substances 0.000 description 3
- 229940075582 sorbic acid Drugs 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010047998 Withdrawal bleed Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940074117 estraderm Drugs 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- DSAYAFZWRDYBQY-UHFFFAOYSA-N 2,5-dimethylhexa-1,5-diene Chemical compound CC(=C)CCC(C)=C DSAYAFZWRDYBQY-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 206010006242 Breast enlargement Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010049513 Luteal phase deficiency Diseases 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940094957 androgens and estrogen Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 208000011803 breast fibrocystic disease Diseases 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940031663 carbomer-974p Drugs 0.000 description 1
- 229940085237 carbomer-980 Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940035811 conjugated estrogen Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940059082 douche Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960004766 estradiol valerate Drugs 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- BLYOHBPLFYXHQA-UHFFFAOYSA-N n,n-bis(prop-2-enyl)prop-2-enamide Chemical compound C=CCN(CC=C)C(=O)C=C BLYOHBPLFYXHQA-UHFFFAOYSA-N 0.000 description 1
- 229960004719 nandrolone Drugs 0.000 description 1
- NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940063238 premarin Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6348597P | 1997-10-21 | 1997-10-21 | |
| US09/170,326 US6306914B1 (en) | 1997-10-21 | 1998-10-13 | Progestin therapy for maintaining amenorrhea |
| PCT/US1998/022169 WO1999020282A1 (en) | 1997-10-21 | 1998-10-21 | Progestin therapy with controlled bleeding |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20002084D0 NO20002084D0 (no) | 2000-04-19 |
| NO20002084L NO20002084L (no) | 2000-06-21 |
| NO326856B1 true NO326856B1 (no) | 2009-03-02 |
Family
ID=26743461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20002084A NO326856B1 (no) | 1997-10-21 | 2000-04-19 | Farmasoytisk sammensetning samt anvendelse av et progestin |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US6306914B1 (ru) |
| EP (1) | EP1032399A1 (ru) |
| JP (1) | JP2003535015A (ru) |
| KR (1) | KR100581308B1 (ru) |
| CN (1) | CN1147301C (ru) |
| AR (1) | AR013981A1 (ru) |
| AU (1) | AU742166C (ru) |
| BR (1) | BR9813262A (ru) |
| CA (2) | CA2307615A1 (ru) |
| HU (1) | HUP0004133A3 (ru) |
| IL (1) | IL135742A (ru) |
| MX (1) | MXPA00003972A (ru) |
| MY (1) | MY121743A (ru) |
| NO (1) | NO326856B1 (ru) |
| NZ (1) | NZ504066A (ru) |
| PE (1) | PE121799A1 (ru) |
| RO (1) | RO121319B1 (ru) |
| RU (2) | RU2261099C2 (ru) |
| WO (1) | WO1999020282A1 (ru) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL127129A (en) * | 1998-11-18 | 2004-06-01 | Ferring Bv | Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared |
| US20040191276A1 (en) * | 1999-11-30 | 2004-09-30 | Cutispharma, Inc. | Compositions and kits for compounding pharmaceuticals |
| US8425892B2 (en) * | 2001-10-29 | 2013-04-23 | Columbia Laboratories, Inc. | Extended, controlled-release pharmaceutical compositions using charged polymers |
| AU2002348272B2 (en) * | 2001-12-05 | 2008-07-31 | Theramex HQ UK Limited | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
| EP1513547A4 (en) * | 2002-05-23 | 2009-11-04 | Michael F Holick | USE OF PEPTIDE ANALOGUES OF PARATHYROID HORMONE FOR THE TREATMENT OF VAGINAL ATROPHY |
| WO2004058110A2 (en) * | 2002-12-24 | 2004-07-15 | Ovion, Inc. | Contraceptive device and delivery system |
| US7772219B2 (en) * | 2003-05-02 | 2010-08-10 | Teva Women's Health, Inc. | Methods of hormonal treatment utilizing extended cycle contraceptive regimens |
| DK1635843T3 (da) * | 2003-06-25 | 2009-05-04 | Bayer Schering Pharma Ag | Terapi, der omfatter dienogest for hormonerstatning og depression |
| CN101001631B (zh) * | 2003-07-16 | 2014-08-06 | 特卫华妇女健康有限公司 | 利用连续给予雌激素的避孕方案的激素治疗方法 |
| CA2569738A1 (en) * | 2004-06-07 | 2005-12-22 | Duramed Pharmaceuticals, Inc. | Dispenser for progestin used for acute and maintenance treatment of dub |
| US20070111975A1 (en) | 2004-10-07 | 2007-05-17 | Duramed Pharmaceuticals, Inc. | Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens |
| JP2009521533A (ja) * | 2005-12-27 | 2009-06-04 | デュラメド ファーマシューティカルズ インコーポレーティッド | 結合型エストロゲン組成物、アプリケーター、キット、ならびにそれらの作製および使用の方法 |
| EP1983998A2 (en) * | 2006-01-20 | 2008-10-29 | Pear Tree Pharmaceuticals, Inc. | Method of treating atrophic vaginitis |
| US8235047B2 (en) | 2006-03-30 | 2012-08-07 | Conceptus, Inc. | Methods and devices for deployment into a lumen |
| US9693953B2 (en) * | 2006-06-02 | 2017-07-04 | Janet A. Chollet | Method of treating atrophic vaginitis |
| GB0616444D0 (en) * | 2006-08-18 | 2006-09-27 | Reckitt Benckiser Nv | Detergent composition |
| WO2008091592A1 (en) | 2007-01-22 | 2008-07-31 | Targacept, Inc. | Intranasal, buccal, and sublingual administration of metanicotine analogs |
| US8828981B2 (en) | 2007-02-06 | 2014-09-09 | George Creasy | Progesterone for the treatment or prevention of spontaneous preterm birth |
| ES2648640T3 (es) | 2008-02-04 | 2018-01-04 | Ferring B.V. | Anillos intravaginales monolíticos que comprenden progesterona y métodos de fabricación y usos de los mismos |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| CA2856520C (en) | 2011-11-23 | 2021-04-06 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| MX2016014281A (es) | 2014-05-22 | 2017-02-22 | Therapeuticsmd Inc | Formulaciones y terapias de reemplazo de combinación de hormonas naturales. |
| BR112016029338A2 (pt) | 2014-07-29 | 2017-08-22 | Therapeuticsmd Inc | creme transdérmico |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| MX2018011705A (es) | 2016-04-01 | 2019-06-10 | Therapeuticsmd Inc | Composicion farmaceutica de hormona esteroide. |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| RU2697369C1 (ru) * | 2018-12-21 | 2019-08-13 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской | Способ дифференциальной диагностики функциональной гипоталамической аменореи на фоне стресса и энергетического дефицита |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| CN113288865B (zh) * | 2021-06-28 | 2022-03-08 | 浙江仙琚制药股份有限公司 | 一种黄体酮阴道凝胶剂的制备方法 |
| CN114983929A (zh) * | 2022-05-16 | 2022-09-02 | 安徽万邦医药科技股份有限公司 | 一种稳定的黄体酮缓释凝胶及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1985002092A1 (en) | 1983-11-14 | 1985-05-23 | Bio-Mimetics Inc. | Bioadhesive compositions and methods of treatment therewith |
| USD345211S (en) | 1992-04-06 | 1994-03-15 | Columbia Laboratories, Inc. | Dispensing vial for feminine hygiene products |
| US5543150A (en) * | 1993-09-15 | 1996-08-06 | Columbia Laboratories, Inc. | Method of progesterone delivery and affect thereof |
| USD375352S (en) | 1994-03-14 | 1996-11-05 | Columbia Laboratories, Inc. | Dispensing vial for feminine hygiene products |
-
1998
- 1998-10-13 US US09/170,326 patent/US6306914B1/en not_active Expired - Fee Related
- 1998-10-21 CN CNB988123894A patent/CN1147301C/zh not_active Expired - Fee Related
- 1998-10-21 CA CA002307615A patent/CA2307615A1/en not_active Abandoned
- 1998-10-21 RU RU2000112650/14A patent/RU2261099C2/ru not_active IP Right Cessation
- 1998-10-21 BR BR9813262-8A patent/BR9813262A/pt not_active Application Discontinuation
- 1998-10-21 CA CA002649671A patent/CA2649671A1/en not_active Abandoned
- 1998-10-21 PE PE1998000990A patent/PE121799A1/es not_active Application Discontinuation
- 1998-10-21 JP JP2000516679A patent/JP2003535015A/ja active Pending
- 1998-10-21 MX MXPA00003972A patent/MXPA00003972A/es not_active IP Right Cessation
- 1998-10-21 MY MYPI98004790A patent/MY121743A/en unknown
- 1998-10-21 KR KR1020007004288A patent/KR100581308B1/ko not_active Expired - Fee Related
- 1998-10-21 RO ROA200000428A patent/RO121319B1/ro unknown
- 1998-10-21 WO PCT/US1998/022169 patent/WO1999020282A1/en not_active Ceased
- 1998-10-21 NZ NZ504066A patent/NZ504066A/xx unknown
- 1998-10-21 AU AU11914/99A patent/AU742166C/en not_active Ceased
- 1998-10-21 HU HU0004133A patent/HUP0004133A3/hu unknown
- 1998-10-21 EP EP98955011A patent/EP1032399A1/en not_active Withdrawn
- 1998-10-21 IL IL13574298A patent/IL135742A/en not_active IP Right Cessation
- 1998-10-22 AR ARP980105256A patent/AR013981A1/es unknown
-
2000
- 2000-04-19 NO NO20002084A patent/NO326856B1/no not_active IP Right Cessation
- 2000-10-17 US US09/833,259 patent/US6593317B1/en not_active Expired - Fee Related
-
2001
- 2001-04-03 US US09/825,569 patent/US20010031747A1/en active Pending
-
2005
- 2005-01-21 RU RU2005101612/14A patent/RU2330667C2/ru not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US20010031747A1 (en) | 2001-10-18 |
| CN1147301C (zh) | 2004-04-28 |
| CN1282250A (zh) | 2001-01-31 |
| RU2005101612A (ru) | 2006-07-10 |
| HUP0004133A3 (en) | 2001-09-28 |
| NO20002084L (no) | 2000-06-21 |
| MY121743A (en) | 2006-02-28 |
| KR20010031299A (ko) | 2001-04-16 |
| RO121319B1 (ro) | 2007-03-30 |
| IL135742A (en) | 2004-09-27 |
| US6593317B1 (en) | 2003-07-15 |
| NZ504066A (en) | 2002-11-26 |
| US6306914B1 (en) | 2001-10-23 |
| AU742166B2 (en) | 2001-12-20 |
| EP1032399A1 (en) | 2000-09-06 |
| HUP0004133A2 (hu) | 2001-05-28 |
| NO20002084D0 (no) | 2000-04-19 |
| AU742166C (en) | 2005-07-14 |
| RU2261099C2 (ru) | 2005-09-27 |
| AU1191499A (en) | 1999-05-10 |
| IL135742A0 (en) | 2001-05-20 |
| CA2649671A1 (en) | 1999-04-29 |
| BR9813262A (pt) | 2000-08-22 |
| KR100581308B1 (ko) | 2006-05-22 |
| JP2003535015A (ja) | 2003-11-25 |
| MXPA00003972A (es) | 2004-04-21 |
| CA2307615A1 (en) | 1999-04-29 |
| PE121799A1 (es) | 1999-12-17 |
| WO1999020282A1 (en) | 1999-04-29 |
| AR013981A1 (es) | 2001-01-31 |
| RU2330667C2 (ru) | 2008-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6306914B1 (en) | Progestin therapy for maintaining amenorrhea | |
| RU2148393C1 (ru) | Новый способ доставки прогестерона и его влияние | |
| JP6082249B2 (ja) | 経皮ゲル製剤 | |
| AU715740C (en) | Progesterone for treating or reducing ischemia | |
| Fitzpatrick et al. | Micronized progesterone: clinical indications and comparison with current treatments | |
| BG106442A (bg) | Мезопрогестини (прогестерон рецептор модулатори) за лечение и профилактика на хормонозависими доброкачествени гинекологични заболявания | |
| Vashisht et al. | A study to look at hormonal absorption of progesterone cream used in conjunction with transdermal estrogen | |
| UA79421C2 (en) | Progestin therapy with regular menstrual bleeding | |
| AU689133C (en) | Novel method of progesterone delivery and affect thereof | |
| Watkinson | The pharmacokinetics of drug delivery systems in hormone replacement therapy | |
| JP2007197459A (ja) | 月経の出血を少なくし維持された効力を持つ超低投与量避妊薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |